On April 2, 2024, MindRank, an innovative drug discovery company driven by clinical-stage artificial intelligence (AI), announced a strategic partnership with BioMetas Co., Ltd., based in Shanghai, for preclinical drug research and development. The two companies will collaboratively integrate resources to advance the construction of a next-generation AI+ drug research and development platform.

This collaboration establishes a new partnership model between platform-based AI drug R&D companies and CRO companies. Leveraging BioMetas's expert pre-clinical R&D team and the world's leading one-stop AI-driven new drug R&D platform independently developed by MindRank, both companies will jointly offer services to clients, expediting the early development of distinctive innovative drugs. Additionally, the two parties will capitalise on the synergy between CRO resource advantages and AI platforms to collectively explore and attain new industrial breakthroughs in AI-enabled drug research and development technology.

About BioMetas:
BioMetas, headquartered in Zhangjiang High-Tech Park, Shanghai, is dedicated to establishing the world's foremost biotechnology R&D service platform. The company offers a comprehensive range of services to global pharmaceutical companies and innovative drug R&D enterprises. These services include target verification, molecular biology, protein expression and purification, antibody expression and purification, in vitro drug screening, cell-level drug screening, in vivo pharmacological efficacy, pharmacokinetics, biological analysis, preclinical drug candidate discovery, and China-US IND filing, providing clients with one-stop drug research and development solutions.

About MindRank:
MindRank is an artificial intelligence (AI)-empowered drug discovery company. By leveraging its proprietary AI platform, Molecule Pro, the company aims to significantly accelerate the drug discovery process and deliver small molecule drugs with desirable efficacy and safety profiles.